Abstract
To the Editor: In a phase 2a study of the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of relapsed or r......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
